X-Chem delivers excellence, innovation and efficiency at each stage of drug discovery. Since 2012, our medicinal chemists have been named as co-inventors on 24 projects, have filed over 100 patents and published more than 65 scientific papers. Our impressive track record includes 17 compounds reaching IND-enabling toxicology studies and seven compounds progressing to Phase I clinical trials or beyond.
Hit → Lead → Candidate: Click through our proven track record of reliability, efficiency and success.
ION Channels
Target:
Sodium Channel Modulator
Therapy Area:
Epilepsy
GPCRs
Target:
H4 Antagonist
Therapy Area:
Inflammation
Transcription Factors
Target:
FOXO1 Inhibitor
Therapy Area:
Diabetes
Kinases
Target:
PINK1 Activator
Therapy Area:
Neurodegeneration
Protein Protein Interactions
Target:
NLRP3 Inhibitor
Therapy Area:
Inflammation
GPCRs
Target:
CXCR7 Modulator
Therapy Area:
Heart Failure
Protein Protein Interactions
Target:
KEAP1 Inhibitor
Therapy Area:
Neurodegeneration
GTPASEs
Target:
Rac Inhibitor
Therapy Area:
Cancer
Epigenetic Regulators
Target:
Bromodomain Inhibitor
Therapy Area:
Inflammation and Cancer
Epigenetic Regulators
Target:
Bromodomain Inhibitor
Therapy Area:
Inflammation and Cancer
Epigenetic Regulators
Target:
Bromodomain Inhibitor
Therapy Area:
Inflammation and Cancer
Epigenetic Regulators
Target:
EED (PRC2) Modulator
Therapy Area:
Blood Disorder
Epigenetic Regulators
Target:
Bromodomain Inhibitor
Therapy Area:
Inflammation and Cancer
GPCRs
Target:
PAR2 Modulator
Therapy Area:
Inflammation
ION Channels
Target:
Sodium Channel Modulator
Therapy Area:
Epilepsy
Lipids
Target:
Ferroptosis Inhibitor
Therapy Area:
Neurodegeneration